Abstract 16228: Quality of Life Improvements at One and Twelve Months Post-TAVR: Results From a Mixed Meta-Regression

BackgroundMany patients with severe aortic stenosis (AS) have the option of transcatheter aortic valve replacement (TAVR). Individual treatment considerations hinge on the likelihood of improvements to quality of life (QOL), especially when uncertainty is amplified by the presence of comorbidities or the necessity of non-transfemoral approaches.MethodsUsing PRISMA guidelines, we conducted an ongoing multi-database search for all trials of TAVR including QOL assessment at 1 and 12 mos post-procedure. Trials were included if they were published in English since 2013 and used either the KCCQ or SF-12 as outcome measures. We performed a mixed-effects meta-regression of extant trial data to determine whether short and long-term quality of life (QOL) improvements attributable to TAVR differed according to patient surgical risk (inoperable, high, or intermediate) or access approach (transfemoral or alternate).ResultsWe identified 29 total trial-cohorts meeting criteria. After removing duplicate analyses, we were left with 15 cohorts including 4383 total patients who received TAVR. Due to heterogeneity of variance, random effects models were fit, illustrating a consistent positive effect on QOL across trials, both at 1mo (log relative mean difference=-0.6, 95% CI-0.91 to -0.37), and 12mos (lrmd=-0.99, 95% CI-1.25 to --0.73). At 1mo, QOL impact was moderated according to whether trans-femoral or alternate approaches were used (p